SYSTEMATIC REVIEW article
Front. Pharmacol.
Sec. Ethnopharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1620340
This article is part of the Research TopicAntiarrhythmic Role of Herbal Medicine and Plant ExtractsView all articles
Efficacy and Safety of Shensong Yangxin Capsules for Persistent Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Provisionally accepted
- 1Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
- 2Capital Medical University, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Shensong Yangxin (SSYX), a standardized Chinese preparation, is widely utilized in arrhythmia treatment. This research sought to assess the clinical advantages of SSYX for persistent atrial fibrillation (PsAF).We searched seven databases and two registries to identify randomized controlled trials (RCTs) assessing SSYX as an adjunctive treatment for PsAF. We assessed methodological quality with the Cochrane Risk of Bias Tool 2.0, and conducted meta-analyses with RevMan 5.4.The meta-analysis incorporated ten RCTs enrolling 1,713 patients with PsAF. SSYX combined with conventional treatments (CTs) significantly lowered the recurrence of AF compared to CTs alone (risk ratio [RR] = 0.65, 95 % conffdence interval [CI] 0.56 to 0.75, P < 0.001). The results also showed that SSYX contributed to the reduction of left atrial diameter (MD = -1.41, 95% CI -2.48 to -0.34, P < 0.001) and P-wave dispersion (MD = -10.37, 95% CI -17.23 to -3.5, P = 0.003). Safety analysis revealed that the combination of SSYX and CTs decreased adverse reaction incidence (RR = 0.54, 95% CI 0.32 to 0.90, P = 0.02). The certainty of evidence was graded as moderate to low.SSYX showed potential in preventing AF recurrence in PsAF patients. Nevertheless, these preliminary findings require validation through more rigorously designed trials, given methodological limitations impacting evidence certainty.
Keywords: Persistent atrial fibrillation, Shensong Yangxin Capsule, Meta-analysis, Systematic review, Traditional Chinese Medicine
Received: 29 Apr 2025; Accepted: 09 Jun 2025.
Copyright: © 2025 Chen, Wang, Li, Runa, Ouyang, Jiang and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zhonghui Jiang, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Zhuye Gao, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.